CN1613442A - 一种有效掩味的口腔崩解片及制备方法 - Google Patents
一种有效掩味的口腔崩解片及制备方法 Download PDFInfo
- Publication number
- CN1613442A CN1613442A CN 200310108459 CN200310108459A CN1613442A CN 1613442 A CN1613442 A CN 1613442A CN 200310108459 CN200310108459 CN 200310108459 CN 200310108459 A CN200310108459 A CN 200310108459A CN 1613442 A CN1613442 A CN 1613442A
- Authority
- CN
- China
- Prior art keywords
- oral cavity
- taste masking
- cavity disintegration
- preparation
- disintegration tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 29
- 239000007884 disintegrant Substances 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 67
- 210000000214 mouth Anatomy 0.000 claims abstract description 35
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960002336 estazolam Drugs 0.000 claims abstract description 22
- 239000008187 granular material Substances 0.000 claims description 46
- 235000019640 taste Nutrition 0.000 claims description 45
- 230000000873 masking effect Effects 0.000 claims description 43
- 238000000576 coating method Methods 0.000 claims description 33
- 239000011248 coating agent Substances 0.000 claims description 32
- 229940079593 drug Drugs 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 19
- 229960001534 risperidone Drugs 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 14
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 14
- 238000012216 screening Methods 0.000 claims description 13
- -1 correctives Substances 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- 239000000314 lubricant Substances 0.000 claims description 11
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 11
- 229960005017 olanzapine Drugs 0.000 claims description 11
- 239000000945 filler Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 9
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 9
- 229940041616 menthol Drugs 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 8
- 235000009508 confectionery Nutrition 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 239000000741 silica gel Substances 0.000 claims description 8
- 229910002027 silica gel Inorganic materials 0.000 claims description 8
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical group O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 5
- 230000003179 granulation Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical group CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- 239000001069 triethyl citrate Substances 0.000 claims description 4
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 4
- 235000013769 triethyl citrate Nutrition 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 2
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 claims description 2
- YTLYLLTVENPWFT-UPHRSURJSA-N (Z)-3-aminoacrylic acid Chemical compound N\C=C/C(O)=O YTLYLLTVENPWFT-UPHRSURJSA-N 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 235000011132 calcium sulphate Nutrition 0.000 claims description 2
- 229960004170 clozapine Drugs 0.000 claims description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229960004391 lorazepam Drugs 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 229960000820 zopiclone Drugs 0.000 claims description 2
- 239000004148 curcumin Substances 0.000 claims 1
- 238000009736 wetting Methods 0.000 claims 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 28
- 238000007873 sieving Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 229920002261 Corn starch Polymers 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 239000008120 corn starch Substances 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229960004756 ethanol Drugs 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000006191 orally-disintegrating tablet Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229920003149 Eudragit® E 100 Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100004286 Caenorhabditis elegans best-5 gene Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002557 soporific effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
名称 | 数量 |
利培酮 | 20g |
玉米淀粉 | 80g |
微晶纤维素 | 20g |
名称 | 含量 |
无水乙醇 | 1000ml |
Eudragit E 100 | 50g |
柠檬酸三乙酯 | 7.5g |
滑石粉 | 20g |
名称 | 数量 |
艾司唑仑 | 10g |
玉米淀粉 | 95g |
交联聚乙烯吡咯烷酮 | 15g |
名称 | 含量 |
95%酒精 | 1000ml |
Eudragit E 100 | 30g |
羟丙基甲基纤维素 | 30g |
蓖麻油 | 6g |
滑石粉 | 20g |
名称 | 数量 |
艾司唑仑 | 10g |
玉米淀粉 | 100g |
微晶纤维素 | 15g |
名称 | 含量 |
无水乙醇 | 1000ml |
羟丙基甲基纤维素 | 50g |
蓖麻油 | 7.5g |
滑石粉 | 20g |
成分 | 单位用量(mg) | 百分比(%) |
掩味利培酮颗粒(13.5%) | 14.8 | 9.25 |
粒状甘露醇 | 73 | 45.62 |
乳糖 | 55 | 34.38 |
微晶纤维素 | 12 | 7.50 |
阿司巴甜 | 1.8 | 1.13 |
薄荷醇 | 0.6 | 0.37 |
硬脂酸镁 | 1.0 | 0.63 |
微粉硅胶 | 1.8 | 1.13 |
合计 | 160 | 100 |
成分 | 单位用量(mg) | 百分比(%) |
掩味艾司唑仑颗粒(6.60%) | 30.3 | 21.64 |
粒状甘露醇 | 96 | 68.57 |
交联聚乙烯吡咯烷酮 | 4 | 2.86 |
低取代羟丙基纤维素 | 5 | 3.57 |
阿司巴甜 | 1.7 | 1.21 |
薄荷醇 | 0.5 | 0.36 |
硬脂酸镁 | 1.0 | 0.71 |
微粉硅胶 | 1.5 | 1.07 |
合计 | 140 | 100 |
成分 | 单位用量(mg) | 百分比(%) |
掩味奥氮平颗粒(26.7%) | 18.7 | 10.39 |
粒状甘露醇 | 75 | 41.67 |
乳糖 | 65 | 36.11 |
微晶纤维素 | 9 | 5.00 |
低取代羟丙基纤维素 | 6 | 3.33 |
阿司巴甜 | 1.8 | 1.00 |
薄荷醇 | 1.0 | 0.56 |
硬脂酸镁 | 2.0 | 1.11 |
微粉硅胶 | 1.5 | 0.83 |
合计 | 180 | 100 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310108459 CN1274298C (zh) | 2003-11-06 | 2003-11-06 | 一种有效掩味的口腔崩解片及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310108459 CN1274298C (zh) | 2003-11-06 | 2003-11-06 | 一种有效掩味的口腔崩解片及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1613442A true CN1613442A (zh) | 2005-05-11 |
CN1274298C CN1274298C (zh) | 2006-09-13 |
Family
ID=34758597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200310108459 Expired - Lifetime CN1274298C (zh) | 2003-11-06 | 2003-11-06 | 一种有效掩味的口腔崩解片及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1274298C (zh) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101754754A (zh) * | 2007-07-23 | 2010-06-23 | 株式会社太平洋 | 含有包覆的含药物的颗粒的可分散药片及其制备方法 |
CN101485636B (zh) * | 2008-01-14 | 2010-12-22 | 齐鲁制药有限公司 | 利培酮口腔崩解片及其制备方法 |
CN102178657A (zh) * | 2011-04-11 | 2011-09-14 | 浙江华海药业股份有限公司 | 一种新型的奥氮平口腔崩解片 |
CN101904824B (zh) * | 2009-06-04 | 2012-07-18 | 齐鲁制药有限公司 | 奥氮平口崩片制剂及其制备方法 |
CN102614140A (zh) * | 2011-01-26 | 2012-08-01 | 浙江九洲药物科技有限公司 | 伊潘立酮口崩片及其制备方法 |
CN102727452A (zh) * | 2011-04-01 | 2012-10-17 | 成都康弘药业集团股份有限公司 | 一种含右佐匹克隆的颗粒及其制备方法 |
CN104546673A (zh) * | 2014-12-25 | 2015-04-29 | 海南卫康制药(潜山)有限公司 | 一种氯硝西泮组合物冻干片及其制备方法 |
CN104546749A (zh) * | 2014-12-25 | 2015-04-29 | 海南卫康制药(潜山)有限公司 | 一种劳拉西泮组合物冻干片及其制备方法 |
CN104546675A (zh) * | 2014-12-25 | 2015-04-29 | 海南卫康制药(潜山)有限公司 | 一种艾司唑仑组合物冻干片及其制备方法 |
CN104586793A (zh) * | 2014-12-25 | 2015-05-06 | 海南卫康制药(潜山)有限公司 | 一种地西泮组合物冻干片及其制备方法 |
CN104586784A (zh) * | 2014-12-25 | 2015-05-06 | 海南卫康制药(潜山)有限公司 | 一种硝西泮组合物冻干片及其制备方法 |
CN104839452A (zh) * | 2008-07-31 | 2015-08-19 | 泰国研究基金会 | 用于鸡饲料添加剂生产的辣椒素的用途 |
CN104887634A (zh) * | 2015-05-07 | 2015-09-09 | 河北龙海药业有限公司 | 奥氮平口腔崩解片及其制备方法 |
CN107080737A (zh) * | 2015-02-02 | 2017-08-22 | 胡小青 | 一种治疗抑郁症的奥氮平口腔崩解片的制备方法 |
CN110151718A (zh) * | 2019-06-13 | 2019-08-23 | 厦门医学院 | 一种奥氮平口腔崩解片及其制备方法 |
CN110507621A (zh) * | 2019-09-17 | 2019-11-29 | 湖南洞庭药业股份有限公司 | 一种劳拉西泮片的制备方法 |
CN112294772A (zh) * | 2020-10-30 | 2021-02-02 | 扬州中宝药业股份有限公司 | 一种硫酸舒欣啶双释放口崩片及其制备方法 |
CN115531335A (zh) * | 2022-11-02 | 2022-12-30 | 合肥医工医药股份有限公司 | 一种磷酸奥司他韦口崩片及其制备方法 |
CN116077450A (zh) * | 2022-12-24 | 2023-05-09 | 东北农业大学 | 一种米氮平掩味口崩片及其制备方法与应用 |
-
2003
- 2003-11-06 CN CN 200310108459 patent/CN1274298C/zh not_active Expired - Lifetime
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101754754A (zh) * | 2007-07-23 | 2010-06-23 | 株式会社太平洋 | 含有包覆的含药物的颗粒的可分散药片及其制备方法 |
CN101485636B (zh) * | 2008-01-14 | 2010-12-22 | 齐鲁制药有限公司 | 利培酮口腔崩解片及其制备方法 |
CN104839452A (zh) * | 2008-07-31 | 2015-08-19 | 泰国研究基金会 | 用于鸡饲料添加剂生产的辣椒素的用途 |
CN104839452B (zh) * | 2008-07-31 | 2019-03-08 | 泰国研究基金会 | 一种辣椒素在鸡饲料生产中的用途 |
CN104839476A (zh) * | 2008-07-31 | 2015-08-19 | 泰国研究基金会 | 用于猪饲料添加剂生产的辣椒素的用途 |
CN101904824B (zh) * | 2009-06-04 | 2012-07-18 | 齐鲁制药有限公司 | 奥氮平口崩片制剂及其制备方法 |
CN102614140A (zh) * | 2011-01-26 | 2012-08-01 | 浙江九洲药物科技有限公司 | 伊潘立酮口崩片及其制备方法 |
CN102614140B (zh) * | 2011-01-26 | 2015-11-25 | 浙江九洲药物科技有限公司 | 伊潘立酮口崩片及其制备方法 |
CN102727452B (zh) * | 2011-04-01 | 2014-12-24 | 成都康弘药业集团股份有限公司 | 一种含右佐匹克隆的颗粒及其制备方法 |
CN102727452A (zh) * | 2011-04-01 | 2012-10-17 | 成都康弘药业集团股份有限公司 | 一种含右佐匹克隆的颗粒及其制备方法 |
CN102178657A (zh) * | 2011-04-11 | 2011-09-14 | 浙江华海药业股份有限公司 | 一种新型的奥氮平口腔崩解片 |
CN102178657B (zh) * | 2011-04-11 | 2017-05-31 | 浙江华海药业股份有限公司 | 一种奥氮平口腔崩解片 |
CN104546675A (zh) * | 2014-12-25 | 2015-04-29 | 海南卫康制药(潜山)有限公司 | 一种艾司唑仑组合物冻干片及其制备方法 |
CN104586793A (zh) * | 2014-12-25 | 2015-05-06 | 海南卫康制药(潜山)有限公司 | 一种地西泮组合物冻干片及其制备方法 |
CN104586784A (zh) * | 2014-12-25 | 2015-05-06 | 海南卫康制药(潜山)有限公司 | 一种硝西泮组合物冻干片及其制备方法 |
CN104546749A (zh) * | 2014-12-25 | 2015-04-29 | 海南卫康制药(潜山)有限公司 | 一种劳拉西泮组合物冻干片及其制备方法 |
CN104546673A (zh) * | 2014-12-25 | 2015-04-29 | 海南卫康制药(潜山)有限公司 | 一种氯硝西泮组合物冻干片及其制备方法 |
CN107080737A (zh) * | 2015-02-02 | 2017-08-22 | 胡小青 | 一种治疗抑郁症的奥氮平口腔崩解片的制备方法 |
CN104887634B (zh) * | 2015-05-07 | 2017-12-26 | 河北龙海药业有限公司 | 奥氮平口腔崩解片及其制备方法 |
CN104887634A (zh) * | 2015-05-07 | 2015-09-09 | 河北龙海药业有限公司 | 奥氮平口腔崩解片及其制备方法 |
CN110151718A (zh) * | 2019-06-13 | 2019-08-23 | 厦门医学院 | 一种奥氮平口腔崩解片及其制备方法 |
CN110507621A (zh) * | 2019-09-17 | 2019-11-29 | 湖南洞庭药业股份有限公司 | 一种劳拉西泮片的制备方法 |
CN112294772A (zh) * | 2020-10-30 | 2021-02-02 | 扬州中宝药业股份有限公司 | 一种硫酸舒欣啶双释放口崩片及其制备方法 |
CN115531335A (zh) * | 2022-11-02 | 2022-12-30 | 合肥医工医药股份有限公司 | 一种磷酸奥司他韦口崩片及其制备方法 |
CN115531335B (zh) * | 2022-11-02 | 2024-01-30 | 合肥医工医药股份有限公司 | 一种磷酸奥司他韦口崩片及其制备方法 |
CN116077450A (zh) * | 2022-12-24 | 2023-05-09 | 东北农业大学 | 一种米氮平掩味口崩片及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1274298C (zh) | 2006-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1274298C (zh) | 一种有效掩味的口腔崩解片及制备方法 | |
CN1196476C (zh) | 口腔内快速崩解片剂的制造方法 | |
TWI600665B (zh) | Low-substituted hydroxypropyl cellulose powder and its production method | |
CN1805738A (zh) | 持续释放的二甲双胍片剂 | |
CN101708336B (zh) | 一种药用预混辅料 | |
CN1309570A (zh) | 赋形剂 | |
CN101584673A (zh) | 一种左乙拉西坦片剂及其制备方法 | |
CN1279899C (zh) | 含支链氨基酸颗粒的生产方法 | |
CN106389344A (zh) | 碳酸钙颗粒及其制备方法 | |
CN105878197A (zh) | 利奥西呱口崩片及其制备方法 | |
WO2007018057A1 (ja) | 口腔内速崩壊錠およびその製造法 | |
CN102114001A (zh) | 一种含有托伐普坦的口服固体制剂 | |
TW201605494A (zh) | 醫藥劑型 | |
CN101053562A (zh) | 奥替溴铵胶囊 | |
JP4774739B2 (ja) | 漢方エキス含有錠剤組成物およびその製造方法 | |
CN1903208A (zh) | 阿德福韦酯口崩片药物制剂及其制备方法 | |
CN1864679A (zh) | 一种复方岩白菜素分散片及其制备方法 | |
JP2022076474A (ja) | リバーロキサバン含有口腔内崩壊錠 | |
CN114129524A (zh) | 对乙酰氨基酚片剂及其制备方法 | |
CN1634045A (zh) | 复方法莫替丁咀嚼片制备方法 | |
CN106265725A (zh) | 一种碳酸钙掩味颗粒剂及其制备方法 | |
KR101509489B1 (ko) | 발사르탄을 함유하는 고형 경구제형의 제조 방법 | |
CN1943562A (zh) | 乌苯美司分散片及其制备方法 | |
CN1839835A (zh) | 一种拉西地平药物制剂的制备方法 | |
CN1857342A (zh) | 沙棘制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20050511 Assignee: CHANGZHOU SIYAO PHARMACY Co.,Ltd. Assignor: CHANGZHOU SIYAO PHARM Co.,Ltd. Contract record no.: 2014320000735 Denomination of invention: Disintegrants for deodoring effectively and their preparation Granted publication date: 20060913 License type: Exclusive License Record date: 20141128 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170601 Address after: 213018 No. 567 Wu Cheng Road, Changzhou, Jiangsu Patentee after: CHANGZHOU SIYAO PHARMACY Co.,Ltd. Address before: 213004, Jiangsu, Changzhou southern suburb of Mei long dam Patentee before: CHANGZHOU SIYAO PHARM Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CX01 | Expiry of patent term |
Granted publication date: 20060913 |
|
CX01 | Expiry of patent term |